Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
Article
Statins and Insulin Resistance
Read time: 1h 1m 1s
About
Media
Watch time: 4m 57s
Articles
Preclinical Diagnosis and Risk Assessment of Atherosclerosis - At Birth? At Event? When is Best?
Citation:
European Cardiology 2011;7(3):164–6
- Views:
508
- Downloads:
0
New Trends and Developments in Patients with Severe Aortic Stenosis - Towards Optimal Treatment?
Citation:
European Cardiology 2009;5(2):81–4
- Views:
399
- Downloads:
0
Atherosclerosis - The Future Challenge for Europe's Health Economies
Citation:
European Cardiology 2009;5(2):86–8
- Views:
482
- Downloads:
0
Cardiovascular Risk Assessment and Primary Prevention in the Era of Plaque Imaging
Citation:
European Cardiology 2008;4(1):12–6
- Views:
137
- Downloads:
0